New WHO Guidelines For HIV Could Boost Single Tablet Uptake In EU
This article was originally published in Scrip
Antiretroviral therapy (ART) should be initiated in everyone living with HIV at any CD4 cell count, according to an early release guideline from the World Health Organization (WHO). This could mean certain HIV medicines see increased use, particularly single-tablet regimens.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.